Navigation Links
Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Date:10/9/2007

Phase 2 Drug Candidate Protects the Ocular Surface Following Exposure to

Controlled Adverse Environment, Reduces Dry Eye Symptoms

LAGUNA HILLS, Calif., Oct. 9 /PRNewswire/ -- Alacrity Biosciences today announced that its dry eye treatment, ALTY-0501, demonstrated statistically significant advantages over vehicle in its ability to control signs and symptoms of dry eye in a Phase 2 study.

The Phase 2 study utilized the controlled adverse environment (CAE) chamber to measure dry eye patients' ability to withstand a stressful drying environment on the eye, and patient diaries to measure the severity of their dry eye symptoms over the course of the study. Patients were randomized to receive ALTY-0501 or its vehicle four times each day over the course of a 56 day study.

Patients who received ALTY-0501 demonstrated statistically significantly lower scores following CAE exposure for fluorescein staining of the total cornea-a measure of damage to the ocular surface-than those who received vehicle (p < 0.05) on day 28. Statistically significant differences from vehicle were also observed with total corneal and conjunctival staining (p < 0.05), superior corneal staining (p < 0.001) and nasal conjunctival staining (p < 0.05).

ALTY-0501 also demonstrated statistically significant advantages compared to vehicle in the patient diary scores measuring the severity of dry eye symptoms over the 56-day study period. Specifically, patient diary scores reflected statistically significantly lower scores for the symptoms of burning (p < 0.0001), stinging (p < 0.0001), and grittiness (p < 0.0001) in the active treated group.

"We have strong evidence that ALTY-0501 can help control patient signs and symptoms by maintaining the epithelial barrier on the surface of the eye," said David F. Power, Alacrity's president and CEO. "We plan to discuss the Phase 2 data and confirm our Phase 2b/3 strategy with the FDA in the fourth quarter of 2007. Our in
'/>"/>

SOURCE Alacrity Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Mindray (NYSE: ... officially released worldwide. The system has been showcased for ... during 14-17th September, and is scheduled for ... Designed to be the most efficient workhorse in ... diagnostic tools with a perfectly optimized user experience including ...
(Date:9/17/2014)... , September 17, 2014 ... to congratulate Biocartis commitment in shipping its first ... long-time investor in Biocartis as part of Debiopharm ... fully automated, real-time PCR based molecular diagnostics system, ... access to clinical molecular diagnostic information, anywhere and ...
(Date:9/16/2014)... Hologic, Inc. (NASDAQ: HOLX ... del Tomcat, un nuovo strumento preanalitico marcato CE ... automatizzata, progettata per semplificare la fase preanalitica ed ... errore legati alla gestione manuale dei campioni. ... riduce il carico di lavoro legato al trasferimento ...
Breaking Medicine Technology:Quality Exams at Your Fingertips 2Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 3
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ) will ... Friday, January 6, 2012 at the Millennium Hotel, 145 West ... Patrick G. LePore, and other members of the senior management ... current products and pipelines, and business outlook to analysts and ...
... Concord Medical Services Holdings Limited (the "Company" or "Concord ... largest network of radiotherapy and diagnostic imaging centers in ... Twelfth Annual CCM Academic Conference in Beijing on December ... conference, doctors and researchers shared their clinical and academic ...
Cached Medicine Technology:Concord Medical Completes its Twelfth Annual Academic Conference 2Concord Medical Completes its Twelfth Annual Academic Conference 3
(Date:9/17/2014)... 2014 As kids settle back ... top of mind for parents, teachers and coaches. ... about concussions and an informative video, Pediatric Concussions: ... coaches and teachers to detect, talk about and ... a pediatric orthopedic surgeon, I witness youth sports ...
(Date:9/17/2014)... 17, 2014 ICS Learning Group, Inc. ... Excellence in Training for the Best Use of Games ... on an online operational safety training module that ICS ... operation. Using an approach that combined realistic 3D ... that was similar to a video game, including competition ...
(Date:9/17/2014)... CA / MANILA, PHILIPPINES (PRWEB) September 17, 2014 ... providing Managed Operations and Business Process Outsourcing (BPO) services ... joined the firm as the Senior Vice President – ... U.S.. , Cary Weltken is a 15 year ... a wealth of experience in helping companies, ranging in ...
(Date:9/17/2014)... Freeslate, Inc. , the ... drug development, today announced that Baylor University acquired ... System to both support Baylor research interests and ... high throughput system is expected to significantly accelerate ... optimization for small molecule organic chemistry. , The ...
(Date:9/17/2014)... 17, 2014 Luxury Barber, the purveyor ... their newest addition to the Regenepure family: The Regenepure ... with nourishing and beneficial ingredients including biotin, silk proteins, ... with ample moisture, while also encouraging volume and shine. ... to complement the Regenepure DR doctor recommended ...
Breaking Medicine News(10 mins):Health News:Video Helps Kids and Adults Talk About Concussion Recognition and Treatment 2Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:MicroSourcing Appoints New Senior Vice President of North America 2Health News:Baylor University Selects Freeslate Reaction Screening System to Support New High Throughput Screening Lab 2Health News:Luxury Barber Adds New Regenepure Biotin Conditioner to Their Selection of Grooming Products 2
... By Steven Reinberg HealthDay Reporter , ... are getting their recommended vaccinations, federal health officials reported ... getting the shots increased 15 percent from 2008 to ... and Prevention. "This is the nation,s report card ...
... A medical researcher at the University of Leicester has made ... Dr Paul Symonds from the Department of Cancer Studies ... particular drug in collaboration with radiotherapy gives significantly better results ... of 1,412 patients from 42 different cancer treatment centres which ...
... HealthDay Reporter , THURSDAY, Aug. 19 (HealthDay News) -- ... increase your risk of dying from a stroke or heart ... for men whose blood pressure was at least 168/100, the ... than non-drinkers if they had downed six drinks on one ...
... 19, 2010The first successful report of using cell-depleted lung as ... embryonic stem cells is presented in a breakthrough article in ... by Mary Ann Liebert, Inc. ( www.liebertpub.com ). The article ... stem cells (ESCs) have the potential to mature into virtually ...
... , THURSDAY, Aug. 19 (HealthDay News) -- The economic downturn ... bank accounts aren,t the only things suffering as unemployment remains ... by Mental Health America and other researchers have found that ... for mental illness, especially such conditions as depression and anxiety. ...
... from an international study she was part of indicates ... cancer survivors are outdated. McNeely, from the Faculty ... surgery are often warned that pressure changes in an ... arm. But the study she did with an Australian ...
Cached Medicine News:Health News:More U.S. Teens Get Recommended Vaccines 2Health News:More U.S. Teens Get Recommended Vaccines 3Health News:Significant advance announced in treatment of cervical cancer 2Health News:Binge Drinking, Hypertension a Deadly Combo 2Health News:Binge Drinking, Hypertension a Deadly Combo 3Health News:Natural lung material is promising scaffold for engineering lung tissue using embryonic stem cells 2Health News:Out of Work May Mean Out of Sorts 2Health News:Out of Work May Mean Out of Sorts 3Health News:Breast cancer survivors don't need to be afraid of air travel: U of A study 2
200 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
Inquire...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Inquire...
Medicine Products: